Please check your internet connection and try again.
# Hepamerz (L-Ornithine L-Aspartate / LOLA)
## Overview
L-Ornithine L-Aspartate (LOLA) is a stable salt of two amino acids used to reduce blood ammonia levels. It acts by stimulating the urea cycle (ornithine) and glutamine synthesis (aspartate) to facilitate the detoxification of ammonia in the liver and skeletal muscle.
## Primary Indications
* Treatment of latent and manifest hepatic encephalopathy (HE).
* Management of hyperammonemia associated with acute or chronic liver disease (e.g., cirrhosis, fatty liver).
## Adult Dosing
* **Oral (Granules):** 3g to 6g administered three times daily (total: 9gā18g per day) after meals.
* **Intravenous:** 10g to 20g (up to 4 ampoules) per 24 hours, administered via infusion. In manifest HE/coma, dosage may be increased up to 40g per 24 hours depending on severity, infused at a rate not exceeding 5g per hour.
* *Note: Always verify specific concentration and infusion rates with local hospital protocols.*
## Pediatric Dosing
* **Safety/Efficacy:** Well-established pediatric data are limited. Use is generally not recommended unless under the guidance of a pediatric hepatologist. Dosage is typically extrapolated based on weight and severity of hyperammonemia.
## Dose Adjustments
* **Renal Impairment:** Use with caution in severe renal impairment (creatinine > 3 mg/dL). Monitoring of serum creatinine and urea is mandatory.
* **Hepatic Impairment:** No downward titration generally required due to the mechanism of action, but monitor for fluid overload during IV administration.
## Contraindications
* Severe renal failure (Creatinine levels > 3 mg/dL).
* Hypersensitivity to L-ornithine L-aspartate.
* Patients with established methylmalonic acidemia or hyperornithinemia.
## Adverse Effects
* **Gastrointestinal:** Nausea, vomiting, abdominal pain, diarrhea, and flatulence.
* **General:** Rare cases of limb pain or allergic reactions (rash).
* *Injection site:* Risk of phlebitis or irritation if extravasation occurs during IV administration.
## Key Drug Interactions
* Minimal clinical interactions documented.
* Avoid mixing with other intravenous medications unless compatibility is confirmed.
## Monitoring
* **Ammonia levels:** Serial monitoring to assess treatment efficacy.
* **Renal function:** Monitor BUN and serum creatinine in patients with baseline impairment.
* **Clinical status:** Monitor mental status/HE grading (West Haven Criteria) to track clinical improvement.
## Clinical Pearls
* LOLA is not a substitute for standard therapy (e.g., Lactulose, Rifaximin) in acute HE but is often used as an adjunct.
* When using IV preparations, ensure the solution is clear; do not combine with other drugs in the same infusion bag.
* For patients with hepatic coma, infusion rates must be strictly controlled to prevent fluid overload or rapid electrolyte imbalance.
* Clinicians should remain aware that hyperammonemia management is secondary to identifying and treating the precipitating factor of the encephalopathy (e.g., GI bleed, infection, constipation).
***
**Educational Disclaimer:** This information is for educational purposes only. Clinical practice varies by region and institution. Always verify specific dosing, safety protocols, and contraindications by consulting your local hospital formulary, the most recent product monograph, or a clinical pharmacist before prescribing or administering medication.
